Access

Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in genomics, we have the obligation to drive down the cost of sequencing, expand access to diagnostics technology, and increase the diversity of genomics data to realize health equity for billions of people around the world.

Videos from this campaign

Stephanie Lheureux, MD, PhD,Princess Margaret Cancer Centre (PMCC).
Illumina Booth at UK Festival of Genomics & Biodata

Content from this campaign

Health & Healthcare

Illumina and Deerfield Management Partner to Accelerate Drug Development
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Deerfield Management, a healthcare investment management firm, today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs.

Health & Healthcare

Illumina Partners With Allelica, Inc.
Customers and our partners represent the heartbeat of Illumina. They help us advance our mission to improve human health through unlocking the power of the genome.

Health & Healthcare

Illumina Announces Long-Term Strategic Partnership with Janssen
I’m proud to announce that today, during the World CDx Summit in London, Illumina, Inc. announced a long-term strategic collaboration with Janssen Biotech, Inc. (Janssen) to accelerate the development of precision medicines.

Health & Healthcare

How Collaboration Is Driving the Next Wave of Genomics
Illumina’s advances in genetic sequencing are reshaping medicine. Genetic sequencing has now allowed cancer patients to find treatment options specific to their tumors, doctors to anticipate adverse drug reactions and personalize medicine, public health agencies around the world to track and detect new COVID variants, and patients with rare diseases to more easily identify and treat their illnesses.

Health & Healthcare

Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced an agreement with Germany's Hannover Medical School (Medizinische Hochschule Hannover (MHH)) to implement the use of whole-genome sequencing (WGS) in critically ill children suspected of having a genetic or rare disease.

Health & Healthcare

Baby Fitz's Life-Saving Diagnosis Through Whole-Genome Sequencing
In June 2019, Christina and Daniel Kettler were barely home from the hospital with their newborn son when they received an urgent phone call.

Health & Healthcare

Illumina Expands Access to Genomics in Latin America Through New State-of-the-Art Solution Center
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of its new state-of-the-art Solution Center in São Paulo, Brazil.

Health & Healthcare

For Kidney Transplant Recipients, a More Accurate and Tailored Care Plan
For years, clinicians have used genomics to better inform treatment and personalize therapies. Now, Verici Dx, an immunodiagnostics company based in Tennessee (US), wants to turn that personalized medicine lens to a different field: kidney transplants.

Health & Healthcare

Join Illumina on World Tuberculosis Day to Raise Awareness and Keep the Fight Up to Eradicate TB
Which infectious disease kills more people in the world than any other?

Sustainable Finance & Socially Responsible Investment

Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications
Illumina logo

More from Illumina

  1. Business
    At Illumina, the faster we can innovate, the more lives we can help save. As a genomics pioneer, we have proven through focused and continued...

  2. People
    Harnessing the world’s best talent and giving them the opportunity to thrive allows us to make world-changing leaps in human health and beyond. Our...

  3. Access
    Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in...

  4. Community
    By sharing our time, talent, and technology, we aim to inspire, support, and empower our communities, our employees, and the next generation.

  5. Environment
    We are committed to integrating environmental stewardship into the way we operate. We recognize the importance of the environment in creating a...

  6. Operating Responsibly
    Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we...